Navigation Links
Resverlogix Notice of Conference Call & Webcast
Date:8/21/2008

TSX Exchange Symbol: RVX

CALGARY, Aug. 21 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that it will host a live teleconference on August 25, 2008 at 11:00 am MDT to provide a corporate update of the Company. Following the presentation there will be a live question and answer session.

The webcast can be accessed at the following link:

http://services.choruscall.com/links/resverlogix080825.html

Participants can also dial in for the conference call:

Dial information is as follows:

North American Toll Free Dial In: 1-800-319-4610

International Dial In: +1-604-638-5340

The webcast will be available on the Resverlogix website for replay for a period of 10 days after the event.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet needs. The NexVas(TM) program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the grievous burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer's and other vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a program that aims to address burgeoning grievous diseases, such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX). For further information please visit http://www.resverlogix.com.

This news release may contain certain forward-looking statements that reflect the current views and/or expectations of Resverlogix Corp. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties
'/>"/>

SOURCE Resverlogix Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Jan Gray Joins Resverlogix Board of Directors
2. Resverlogixs Lead Drug Featured in Key Scientific Publication
3. Industry Leaders Select Resverlogixs RVX-208
4. /C O R R E C T I O N from Source -- Resverlogix Corp./
5. Resverlogix Notice of Conference Call & Webcast
6. Resverlogix Share Option Extension
7. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
8. Resverlogix Honoured with World Economic Forum Technology Pioneer Award
9. Resverlogix is Presenting at IAS HDL Workshop
10. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Virobay, Inc. ... for pain has reached an important milestone, as Virobay ... VBY-036 - a selective cathepsin S inhibitor.   ... a double-blind, randomized, placebo-controlled study designed to evaluate the ... VBY-036 in healthy adults. "The initiation of ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 On April ... trips to supermarkets to search for the growing antibiotic ... aisles. Results from a year long study were released ... in foods, specifically meats, over previous years. For those ... the growth of antibiotic resistant bacteria in food, may ...
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... SOUTH EASTON, Mass. , May 23, 2013 /PRNewswire/ ... "Company") today announced that the Company will host a ... and to provide a business update. The teleconference information ... 2013 Time: 11:00 a.m. Eastern Daylight Time (EDT) ... Canada ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
Breaking Biology Technology:Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... , , , ... AMGN ) today announced detailed results from a Phase ... the treatment of bone metastases in 2,046 patients with advanced ... demonstrated superior efficacy compared to Zometa. These results were presented ...
... ... answer the question, "Is the Jatropha sector becoming a DotCom Bubble?". 2nd JatrophaWorld ... Viridesco Ltd. will discuss the challenges, controversies & paradoxes of the nascent Jatropha non-food ... ...
... has become just another fixture, it,s time to take a ... used to develop paper-based biosensors that can detect certain harmful ... bioterrorism agents. In a paper published in the July ... research team at McMaster University, working with the Sentinel Bioactive ...
Cached Biology Technology:Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 2Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 3Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 4Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 5Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 6Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 7Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 8Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients 9Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel 2Toxin detection as close as an inkjet printer 2
(Date:5/23/2013)... the natural history museums of the world are billions ... beetles to flowers, mushrooms and grasses, all stacked, stored ... rich and diverse collections could be critical to understanding ... of a growing human footprint if only the ... brought to life with the help of a team ...
(Date:5/22/2013)... 22, 2013 U.S. Forest Service scientists are part ... funding from the TKF Foundation, will examine how collaborative ... individuals recover from tragedy. , The TKF Foundation announced ... projects selected for grant funding. In addition to research ... in recovery and resiliency, the 3-year, $585,000 grant will ...
(Date:5/22/2013)... join together in a major new effort to educate ... providing Earth,s people with clean water that looms ahead ... comment article in the current edition of Chemical ... American Chemical Society (ACS), the world,s largest scientific society. ... and Jerald L. Schnoor, Ph.D., explain that shortages of ...
Breaking Biology News(10 mins):CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4'Landscapes of Resilience' to study how people use nature as a source of recovery 2
... in German . The isotopic analysis of ... Asia, the 40,000 year old skeleton from Tianyuan Cave in ... team of researchers from the Max Planck Institute for Evolutionary ... Sciences and the Institute of Vertebrate Paleontology and Paleoanthropology in ...
... research paper co-written by a Virginia Tech faculty member ... that is unusually large for its species. The findings ... Physical Review Letters . The article, "Acoustic ... by Z. Zhang, R. Mller, and S.N. Truong, details ...
... publish results from the analysis of the putative remains ... in a book from Museum Gustavianum, Uppsala University, was ... to identify the remains of Nicolaus Copernicus (1473-1543), found ... collaborative project between Swedish and Polish scientists in a ...
Cached Biology News:Fish on the menu of our ancestors 2Mystery of bat with an extraordinary nose solved 2Analysis of Copernicus putative remains support identity 2
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
... 4 deuterium atoms at the 9, 10, 12, ... as an internal standard for the quantification of ... produced by the lipoxygenation of linoleic acid in ... in atherosclerotic plaques, as an esterified component of ...
5(S)-HETE-d8 is used as an internal standard for the quantification of 5(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: